TY - JOUR
T1 - 18F-sodium fluoride PET/CT in oncology
T2 - An atlas of SUVs
AU - Sabbah, Nathanael
AU - Jackson, Tatianie
AU - Mosci, Camila
AU - Jamali, Mehran
AU - Minamimoto, Ryogo
AU - Quon, Andrew
AU - Mittra, Erik S.
AU - Iagaru, Andrei
N1 - Publisher Copyright:
Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/4/21
Y1 - 2015/4/21
N2 - Purpose: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. Patients andMethods: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes Results: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUVmax for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. Conclusions: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.
AB - Purpose: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. Patients andMethods: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUVmax and SUVmean for bony metastases and degenerative changes Results: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUVmax for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. Conclusions: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.
KW - Atlas
KW - F-NaF
KW - PET/CT
KW - SUV
UR - http://www.scopus.com/inward/record.url?scp=84925423901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925423901&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000000633
DO - 10.1097/RLU.0000000000000633
M3 - Article
C2 - 25546225
AN - SCOPUS:84925423901
SN - 0363-9762
VL - 40
SP - e228-e231
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 4
ER -